Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.

about

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q39023377

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Germline polymorphisms as biom ...... atic review and meta-analysis.

@en

Germline polymorphisms as biom ...... atic review and meta-analysis.

@nl

type

Item

label

Germline polymorphisms as biom ...... atic review and meta-analysis.

@en

Germline polymorphisms as biom ...... atic review and meta-analysis.

@nl

prefLabel

Germline polymorphisms as biom ...... atic review and meta-analysis.

@en

Germline polymorphisms as biom ...... atic review and meta-analysis.

@nl

P1476

Germline polymorphisms as biom ...... matic review and meta-analysis

@en

P2093

C J O'Callaghan

http://www.w3.org/2001/XMLSchema#string

D J Jonker

http://www.w3.org/2001/XMLSchema#string

D Tu

http://www.w3.org/2001/XMLSchema#string

E K Morgen

http://www.w3.org/2001/XMLSchema#string

F Graziano

http://www.w3.org/2001/XMLSchema#string

G Liu

http://www.w3.org/2001/XMLSchema#string

G Milano

http://www.w3.org/2001/XMLSchema#string

H-J Lenz

http://www.w3.org/2001/XMLSchema#string

J Zalcberg

http://www.w3.org/2001/XMLSchema#string

P2860

Why most published research findings are false

Cetuximab for the treatment of colorectal cancer.

Quantifying heterogeneity in a meta-analysis

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Meta-analysis when only the median survival times are known: a comparison with individual patient data results.

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

P2888

tpj.2016.56

P304

535-542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1038/TPJ.2016.56

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Dobrovic

Christos S Karapetis

P577

2016-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27897268

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

biomarker